Clinical Trial Update: Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating 24 months of bezafibrate for primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis
• Cholestasis
• Sclerosing Cholangitis

Drugs mentioned

• Bezafibrate (bezafibrate)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Primary Sclerosing Cholangitis, Cholestasis | Phase 3 | Status: UNKNOWN